Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 146 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo (Part II) Clear all

Conditions: Basal Cell Carcinoma
Interventions: Doxorubicin-containing MNA, Placebo-containing MNA; Combination Product · Drug
Lead sponsor: SkinJect, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: West Palm Beach, Florida • New York, New York

Conditions: Ankylosing Spondylitis
Interventions: AIN457, Placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 10
States / cities: Paradise Valley, Arizona • Springfield, Illinois • Oklahoma City, Oklahoma + 6 more

Conditions: Inclusion Body Myositis
Interventions: ABC008; Drug
Lead sponsor: Abcuro, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 34
States / cities: Phoenix, Arizona • Irvine, California • Los Angeles, California + 27 more

Conditions: Acute Kidney Injury
Interventions: GDC-8264, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Stanford, California • Tampa, Florida • Lutherville, Maryland + 6 more

Conditions: Systemic Juvenile Idiopathic Arthritis With Active Flare
Interventions: canakinumab, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 19 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 12
States / cities: Little Rock, Arkansas • Washington D.C., District of Columbia • Chicago, Illinois + 6 more

Conditions: Orthopaedic Fractures
Interventions: NSAID, Gabapentinoids, placebo; Drug
Lead sponsor: Major Extremity Trauma Research Consortium; Other
Eligibility: 18 Years to 80 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 17
States / cities: Miami, Florida • West Palm Beach, Florida • Indianappolis, Indiana + 13 more

Conditions: Lung Cancer, Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
Interventions: Ipilimumab, Placebo, Paclitaxel, Carboplatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 27
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 24 more

Conditions: Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
Interventions: Deucrictibant low dose, Deucrictibant high dose, Placebo; Drug
Lead sponsor: Pharvaris Netherlands B.V.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • St Louis, Missouri

Conditions: Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
Interventions: M7824, Placebo, Gemcitabine, Cisplatin; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 12
States / cities: Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 9 more

Conditions: Pancreatic Neoplasms, Pancreatic Cancer
Interventions: Bardoxolone methyl, Gemcitabine, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 5
States / cities: Denver, Colorado • Ocoee, Florida • Indianapolis, Indiana + 2 more

Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions: oxaliplatin, leucovorin calcium, capecitabine, bevacizumab, fluorouracil, laboratory biomarker analysis; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: ZD6474, Placebo, ZD1839; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 18
States / cities: Pine Bluff, Arkansas • Los Angeles, California • Palm Springs, California + 15 more

Conditions: Systemic Lupus Erythematosus
Interventions: Placebo, Rontalizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 49
States / cities: Anniston, Alabama • Birmingham, Alabama • Tucson, Arizona + 40 more

Conditions: Healthy Volunteer
Interventions: Gantenerumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Covid19
Interventions: Low Dose of KBP-COVID-19, High Dose of KBP-COVID-19, Placebo; Biological
Lead sponsor: KBio Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: West Palm Beach, Florida • Meridian, Idaho • Winston-Salem, North Carolina + 3 more

Conditions: Idiopathic Pulmonary Fibrosis, Hypoxemia
Interventions: GBT440, Placebo; Drug
Lead sponsor: Global Blood Therapeutics; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 12
States / cities: Birmingham, Alabama • San Francisco, California • Denver, Colorado + 9 more

Conditions: Colon Cancer
Interventions: Vigil™ Vaccine, Placebo; Biological · Drug
Lead sponsor: Gradalis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Osteoarthritis, Post-traumatic Osteoarthritis
Interventions: amobarbital/Gel-One (one dose), Placebo (single dose), amobarbital/Gel-One (two doses), Placebo (two doses); Drug
Lead sponsor: J L Marsh; Other
Eligibility: 18 Years to 60 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Age-Related Macular Degeneration
Interventions: alpha lipoic acid, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 55 Years to 90 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 5
States / cities: Iowa City, Iowa • Teaneck, New Jersey • Eugene, Oregon + 2 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Part A: RPL554, Part B: RPL554, Placebos; Drug
Lead sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Union, South Carolina

Conditions: Advanced Malignant Neoplasm, Dermatologic Complication
Interventions: Doxycycline, Management of Therapy Complications, Placebo, Questionnaire Administration, Spironolactone, Sunscreen, Therapeutic Hydrocortisone; Drug · Procedure · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Urbana, Illinois • Des Moines, Iowa • Wichita, Kansas + 2 more

Conditions: Peanut Allergy
Interventions: Peanut SLIT-tablet, Placebo; Biological · Other
Lead sponsor: ALK-Abelló A/S; Industry
Eligibility: 4 Years to 65 Years
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 33
States / cities: Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 25 more

Conditions: Recurrent Skin Cancer, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Squamous Cell Carcinoma of the Skin, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity
Interventions: erlotinib hydrochloride, linsitinib, placebo, radiation therapy, therapeutic conventional surgery, laboratory biomarker analysis; Drug · Radiation · Procedure + 1 more
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Traumatic Brain Injury, Post-traumatic Stress Disorder
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Houston, Texas

Search by objective public record fields.

Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)

Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)

Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Improving Pain Management and Long Term Outcomes Following High Energy Orthopedic Trauma (Pain Study)

Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer

Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer

This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus

A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers

KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers

Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF

Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases

Translating Metabolic Responses to Mechanical Insult Into Early Interventions to Prevent PTOA

Alpha Lipoic Acid in Geographic Atrophy

Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler

Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab

Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)

Mission Connect Mild Traumatic Brain Injury (TBI) Integrated Clinical Protocol